Alivecorfade.png

Ambulatory Monitoring of Arrhythmias: Innovation & The Case For Adopting
March 17th 14:00-15:00

Supported By

alivecor.png

Overview

Cardiovascular disease (CVD) is the leading cause of death in the UK, yet is largely preventable. It is the single biggest area where the NHS can save lives over the next decade, and as such, is a core priority in the NHS Long Term Plan.

With the onset of the COVID-19 pandemic, came an acceleration in adoption of technology as a tool within the NHS - both in clinic and in community - to enhance patient outcomes and professional pathways.

These available technologies have a significant role to play, both broadly in alignment with the NHS LTP and also more specifically in the quest to close the atrial fibrillation detection gap.

This webinar will highlight the technologies available to the NHS for ambulatory monitoring of CVD and also showcase recent NICE recommendation of the first and only personal ECG to achieve such status. Speaking on this topic will be Trudie Lobban, CEO and Founder of the Arrhythmia Alliance, and Dr Matt Reed, Consultant in Emergency Medicine, Edinburgh.

Speakers

unnamed-1.jpg

Breid O Brien

Deputy Director Digital Health, NHSX

profile (3).png

Confirmed

Untitled-1.png

Trudie Lobban MBE

CEO of Arrythmia Alliance

profile (3).png

Confirmed

unnamed-3.jpg

Dr Matt Reed

Consultant in Emergency Medicine, Edinburgh, NHS Lothian

profile (3).png

Confirmed